« Back
Home /
CYP2C19 Antibody (N-term) Blocking Peptide

CYP2C19 Antibody (N-term) Blocking Peptide

Manufacturer	Abcepta
Category	Peptides & Proteins Peptides
Type	Peptides
Specific against	other
Format	Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
Amount	500 ug
Item no.	ABC-BP6710a
eClass 6.1	34160400
eClass 9.0	32160409
Available
Primary Accession	P33261
Bio Background	CYP2C19 is a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and is known to metabolize many xenobiotics, including the anticonvulsive drug mephenytoin, omeprazole, diazepam and some barbiturates. Polymorphism within its gene is associated with variable ability to metabolize mephenytoin, known as the poor metabolizer and extensive metabolizer phenotypes.
Bio References	Shuldiner, A.R., JAMA 302 (8), 849-857 (2009)Nelson, D.R., Pharmacogenetics 14 (1), 1-18 (2004)
Gene ID	1557
Gene Name	CYP2C19
Subtitle	Synthetic peptide
Target/Specificity	The synthetic peptide sequence used to generate the antibody AP6710a was selected from the N-term region of human CYP2C19. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

ABC-BP6710a-datasheet.pdf

Request safety datasheet

Simple Order Order Subscription

Amount: 500 ug

available

Delivery expected until 7/4/2024